Aligos Therapeutics (ALGS) Insider Trading & Ownership $6.04 -0.01 (-0.08%) As of 02:59 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Aligos Therapeutics (NASDAQ:ALGS) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage8.75%Number OfInsiders Buying(Last 3 Years)1Amount OfInsider Buying(Last 3 Years)$6.03 MNumber OfInsiders Selling(Last 3 Years)0 Get ALGS Insider Trade Alerts Want to know when executives and insiders are buying or selling Aligos Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address ALGS Insider Buying and Selling by Quarter Aligos Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails10/25/2023Carole NuechterleinDirectorBuy317,344$19.00$6,029,536.00 (Data available from 1/1/2013 forward) ALGS Insider Trading Activity - Frequently Asked Questions Who is on Aligos Therapeutics's Insider Roster? The list of insiders at Aligos Therapeutics includes Carole Nuechterlein. Learn more on insiders at ALGS. What percentage of Aligos Therapeutics stock is owned by insiders? 8.75% of Aligos Therapeutics stock is owned by insiders. Learn more on ALGS's insider holdings. Which Aligos Therapeutics insiders have been buying company stock? The following insider purchased ALGS shares in the last 24 months: Carole Nuechterlein ($6,029,536.00). How much insider buying is happening at Aligos Therapeutics? Insiders have purchased a total of 317,344 ALGS shares in the last 24 months for a total of $6,029,536.00 bought. Aligos Therapeutics Key ExecutivesDr. Lawrence M. Blatt MBA (Age 62)Ph.D., CEO, President & Chairman of the Board Compensation: $1.03MDr. Julian A. Symons DPHIL (Age 62)Executive VP & Chief Scientific Officer Compensation: $735.51kDr. Matthew W. McClure M.D. (Age 52)Executive VP & Chief Medical Officer Compensation: $740.39kKristina EngesethVP and Head of People & CultureDr. Sushmita M. Chanda DABT (Age 57)Ph.D., Executive Vice President & Chief Development Officer Dr. David B. Smith Ph.D.Executive VP & Head of Chemical OperationsDr. Tse-I Lin Ph.D.VP of Early Compound Development & Belgian Site Head More Insider Trading Tools from MarketBeat Related Companies ENTA Insider Ownership EDIT Insider Ownership NLTX Insider Ownership NMRA Insider Ownership LXEO Insider Ownership SNTI Insider Ownership RAPT Insider Ownership CCCC Insider Ownership ZNTL Insider Ownership ALEC Insider Ownership Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles McDonald’s Insiders Sell Shares! Investors Should Do the Opposite5 Mid-Cap Stocks Insiders Are Buying This YearInsider Buying in This Stock Reiterates Analysts Bullish OutlookBeware of BigBear.ai: Insiders Are Selling—Should You?XPO Buying $50 Million of Its Own Stock: Here's Why This page (NASDAQ:ALGS) was last updated on 5/2/2025 by MarketBeat.com Staff From Our PartnersElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | SponsoredTrump Orders 'National Digital Asset Stockpile'Billionaires Rush Into Digital Banking Token Three massive forces are converging right now, creating what c...Crypto 101 Media | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | SponsoredThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredFeds Just Admitted It—They Can Take Your CashThe Government Just Said Your Money Isn't Yours That's right—According to the DOJ, YOUR hard-earned money i...Priority Gold | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aligos Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aligos Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ALGS Stock Free ALGS Stock Alerts